Relatlimab
drugOn this page
Also known as BMS-986016Relatlimab component of bms-986213Relatlimab component of opdualag -rmbwRelatlimab rmbwRelatlimab-rmbw
Summary
Relatlimab (CHEMBL3990044) is an approved antibody targeting LAG3; indicated across 31 conditions including colorectal carcinoma and colorectal adenocarcinoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- Targets: 1 (LAG3)
- Indications: 31 conditions
- Clinical trials: 76
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3990044 |
| Name | Relatlimab |
| Type | Antibody |
| Max phase | 4 |
Also known as: BMS-986016, Relatlimab, Relatlimab component of bms-986213, Relatlimab component of opdualag -rmbw, Relatlimab rmbw, Relatlimab-rmbw, RELATLIMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| LAG3 | LAG3 (CD223) | Antagonist | 0.1% | P18627 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): LAG3.
Top Reactome pathways
3 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Adaptive Immune System | 1 | LAG3 |
| Immune System | 1 | LAG3 |
| MHC class II antigen presentation | 1 | LAG3 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| adaptive immune response | 1 |
| plasmacytoid dendritic cell activation | 1 |
| negative regulation of T cell mediated immune response to tumor cell | 1 |
| cell surface receptor signaling pathway | 1 |
| negative regulation of interleukin-2 production | 1 |
| T cell activation | 1 |
| natural killer cell mediated cytotoxicity | 1 |
| innate immune response | 1 |
| negative regulation of regulatory T cell differentiation | 1 |
| positive regulation of natural killer cell mediated cytotoxicity | 1 |
| regulation of immune response | 1 |
| negative regulation of T cell receptor signaling pathway | 1 |
| negative regulation of T cell activation | 1 |
| immune system process | 1 |
Indications & clinical
Indications
31 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| colorectal carcinoma | 3 | MONDO:0024331 | EFO:1001951 |
| colorectal adenocarcinoma | 3 | MONDO:0005008 | EFO:0000365 |
| melanoma | 3 | MONDO:0005105 | EFO:0000756 |
| metastatic melanoma | 3 | MONDO:0005191 | EFO:0002617 |
| colorectal neoplasm | 3 | MONDO:0005335 | EFO:0004142 |
| cutaneous melanoma | 3 | MONDO:0005012 | EFO:0000389 |
| plasma cell myeloma | 2 | MONDO:0009693 | EFO:0001378 |
| head and neck squamous cell carcinoma | 2 | MONDO:0010150 | EFO:0000181 |
| hepatocellular carcinoma | 2 | MONDO:0007256 | EFO:0000182 |
| acute myeloid leukemia | 2 | MONDO:0018874 | EFO:0000222 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| renal cell carcinoma | 2 | MONDO:0005086 | EFO:0000681 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| basal cell carcinoma | 2 | MONDO:0020804 | EFO:0004193 |
| soft tissue sarcoma | 2 | MONDO:0018078 | EFO:1001968 |
| gastric neoplasm | 2 | MONDO:0021085 | MONDO:0001056 |
| chordoma | 2 | MONDO:0008978 | MONDO:0008978 |
| squamous cell carcinoma | 2 | MONDO:0005096 | EFO:0000707 |
| colon carcinoma | 2 | MONDO:0002032 | EFO:1001950 |
| uveal melanoma | 2 | MONDO:0006486 | EFO:1000616 |
| cutaneous neuroendocrine carcinoma | 2 | MONDO:0019210 | EFO:1001471 |
| nasopharyngeal carcinoma | 2 | MONDO:0015459 | MONDO:0015459 |
| glioblastoma | 1 | MONDO:0018177 | EFO:0000519 |
| gliosarcoma | 1 | MONDO:0016681 | EFO:1001465 |
| hematopoietic and lymphoid system neoplasm | 1 | MONDO:0002334 | MONDO:0044881 |
| diffuse large B-cell lymphoma | 1 | MONDO:0018905 | EFO:0000403 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
| follicular lymphoma | 1 | MONDO:0018906 | MONDO:0018906 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 76.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 39 |
| PHASE1/PHASE2 | 12 |
| PHASE1 | 11 |
| PHASE3 | 5 |
| Not specified | 4 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07459543 | PHASE4 | NOT_YET_RECRUITING | A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India |
| NCT07504796 | PHASE4 | RECRUITING | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab |
| NCT03470922 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma |
| NCT05625399 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma |
| NCT05987241 | PHASE2/PHASE3 | RECRUITING | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study |
| NCT06112314 | PHASE3 | RECRUITING | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) |
| NCT06246916 | PHASE3 | RECRUITING | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) |
| NCT06264180 | PHASE3 | RECRUITING | VO and Nivolumab vs Physician’s Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] |
| NCT06561386 | PHASE3 | RECRUITING | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% |
| NCT02465060 | PHASE2 | ACTIVE_NOT_RECRUITING | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
| NCT03026140 | PHASE2 | RECRUITING | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer |
| NCT03521830 | PHASE2 | RECRUITING | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma |
| NCT03607890 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor |
| NCT03610711 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer |
| NCT03899155 | PHASE2 | RECRUITING | Pan Tumor Rollover Study |
| NCT04080804 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer |
| NCT04205552 | PHASE2 | RECRUITING | Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients |
| NCT04623775 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) |
| NCT04953104 | PHASE2 | ACTIVE_NOT_RECRUITING | ARID1A and/or KDM6A Mutation and CXCL13 Expression |
| NCT05034536 | PHASE2 | ACTIVE_NOT_RECRUITING | PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma |
| NCT05148546 | PHASE2 | ACTIVE_NOT_RECRUITING | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer |
| NCT05347212 | PHASE2 | ACTIVE_NOT_RECRUITING | Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla |
| NCT05418972 | PHASE2 | ACTIVE_NOT_RECRUITING | A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma |
| NCT05428007 | PHASE2 | RECRUITING | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma |
| NCT05704647 | PHASE2 | RECRUITING | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases |
| NCT06029270 | PHASE2 | RECRUITING | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer |
| NCT06101134 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations |
| NCT06237920 | PHASE2 | RECRUITING | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab |
| NCT06295159 | PHASE2 | RECRUITING | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma |
| NCT06683755 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) |
| NCT06697197 | PHASE1/PHASE2 | RECRUITING | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors |
| NCT06816927 | PHASE2 | RECRUITING | Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab |
| NCT07281924 | PHASE1/PHASE2 | RECRUITING | Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis |
| NCT07369791 | PHASE2 | NOT_YET_RECRUITING | Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. |
| NCT01968109 | PHASE1/PHASE2 | COMPLETED | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors |
| NCT02060188 | PHASE2 | COMPLETED | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread |
| NCT02061761 | PHASE1/PHASE2 | COMPLETED | A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies |
| NCT02488759 | PHASE1/PHASE2 | COMPLETED | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors |
| NCT02519322 | PHASE2 | COMPLETED | Neoadjuvant and Adjuvant Checkpoint Blockade |
| NCT02750514 | PHASE2 | TERMINATED | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).